DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.28
−2.69%1
Insider buys (3m)
46
Insider sells (3m)
-$113.5M
Net value (3m)
+43.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Lucera Erick · officer: Chief Financial Officer | Sale | 1,797 | $26 |
| Aug 17, 2026 | Rhodes Jason P · director | Sale | 94,415 | $26 |
| Aug 17, 2026 | Rhodes Jason P · director | Sale | 1,359,674 | $25 |
| Aug 17, 2026 | Rhodes Jason P · director | Sale | 322,465 | $25 |
| Aug 17, 2026 | Rhodes Jason P · director | Sale | 478,377 | $25 |
| Aug 17, 2026 | Friedl-Naderer Johanna · officer: Chief Commercial Officer | Sale | 226 | $26 |
| Aug 17, 2026 | Rhodes Jason P · director | Sale | 63,643 | $26 |
| Aug 17, 2026 | Kerr Douglas · officer: Chief Medical Officer | Sale | 1,556 | $26 |
| Aug 17, 2026 | Cox John · director, officer: CEO & President | Sale | 4,986 | $26 |
| Aug 17, 2026 | Rhodes Jason P · director | Sale | 268,354 | $26 |
| Jul 29, 2026 | Kersten Dirk · director | Sale | 5,388 | $26 |
| Jul 29, 2026 | Kersten Dirk · director | Sale | 256,072 | $26 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 253,039 | $23 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 29,587 | $24 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 127,182 | $23 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 49,193 | $23 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 11,665 | $24 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 14,844 | $24 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 124,379 | $23 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 5,000 | $24 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 62,543 | $23 |
| Jul 8, 2026 | Rhodes Jason P · director | Sale | 100,019 | $23 |
| Jun 30, 2026 | Rhodes Jason P · director | Sale | 51,756 | $21 |
| Jun 30, 2026 | Rhodes Jason P · director | Sale | 162,954 | $21 |
| Jun 30, 2026 | Rhodes Jason P · director | Sale | 40,702 | $21 |
| Jun 30, 2026 | Rhodes Jason P · director | Sale | 64,411 | $21 |
| Jun 30, 2026 | Rhodes Jason P · director | Sale | 81,903 | $21 |
| Jun 30, 2026 | Rhodes Jason P · director | Sale | 102,969 | $21 |
| Jun 26, 2026 | Rhodes Jason P · director | Sale | 5,019 | $21 |
| Jun 26, 2026 | Rhodes Jason P · director | Sale | 6,382 | $21 |
Institutional positioning
13F filings over the trailing two quarters
New 92Increased 190Reduced 140Sold out 30
| Filer | Action | Shares | Filed |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | Increased | 30,912,287 | Aug 14, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Increased | 30,785,801 | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 13,647,376 | May 18, 2026 |
| BlackRock, Inc. | Increased | 12,404,330 | Aug 7, 2026 |
| Jupiter Topco LLC | New Position | 11,997,738 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 11,699,870 | May 13, 2026 |
| FMR LLC | Increased | 11,207,000 | Aug 13, 2026 |
| ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | Unchanged | 9,130,465 | May 14, 2026 |
| FMR LLC | Increased | 8,908,980 | May 15, 2026 |
| STATE STREET CORP | Increased | 7,458,263 | Aug 7, 2026 |
| Orbis Allan Gray Ltd | Increased | 7,006,542 | Aug 14, 2026 |
| Atlas Venture Life Science Advisors, LLC | Reduced | 6,800,099 | Aug 13, 2026 |
| ORBIS ALLAN GRAY LTD | Increased | 6,762,231 | May 15, 2026 |
| STATE STREET CORP | Reduced | 6,653,746 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 6,405,069 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 17, 2026